BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36682147)

  • 1. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
    Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
    Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
    Fan C; Zhong T; Yang H; Yang Y; Wang D; Yang X; Xu Y; Fan Y
    Eur J Med Chem; 2020 Mar; 190():112108. PubMed ID: 32058239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
    Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
    Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition.
    Li M; Wang D; Li Q; Luo F; Zhong T; Wu H; Xiong L; Yuan M; Su M; Fan Y
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1.
    Fan Y; Zhang F; Xiong L; Su M; Luo F; Li M; Li Q; Zhong T; Yuan M; Xu Y; Mu S; Yang H
    Bioorg Chem; 2023 Jun; 135():106484. PubMed ID: 36963371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
    Dong C; Chen Y; Li H; Yang Y; Zhang H; Ke K; Shi XN; Liu X; Li L; Ma J; Kung HF; Chen C; Lin MC
    Int J Biol Sci; 2019; 15(7):1523-1532. PubMed ID: 31337981
    [No Abstract]   [Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3Kα inhibitor DFX24 suppresses tumor growth and metastasis in non-small cell lung cancer via ERK inhibition and EPHB6 reactivation.
    Fan YH; Ding HW; Kim D; Liu JY; Hong JY; Xu YN; Wang D; Yang XS; Lee SK
    Pharmacol Res; 2020 Oct; 160():105147. PubMed ID: 32814167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.
    Yang YQ; Chen H; Liu QS; Sun Y; Gu W
    Bioorg Chem; 2020 Jul; 100():103845. PubMed ID: 32344183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
    Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
    Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
    Qi B; Xu X; Yang Y; He H; Yue X
    Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
    Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
    Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
    Ibrahim BT; Allam HA; El-Dydamony NM; Fouad MA; Mohammed ER
    Drug Dev Res; 2024 Apr; 85(2):e22163. PubMed ID: 38419305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.